Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment

Topical treatments remain the primary therapeutic strategy for glaucoma, with the primary objective of reducing intraocular pressure (IOP), the only modifiable risk factor for the disease. While these medications are effective in lowering IOP, they are also associated with a variety of potential adverse effects. This study aims to compare the effects of various topical antiglaucoma medications on the ocular surface in patients with open-angle glaucoma or intraocular hypertension. Patients were classified based on their treatment type and assessed using the Schirmer test, tear break-up time (TBUT), and fluorescein staining. The monitoring period spanned from February 2019 to September 2024. Preliminary results suggested that the daily number of drops administered may have a more significant impact on outcomes than the presence or absence of preservatives in the eye drops.